New hope: immune drug may replace chemo for rare nasal lymphoma
NCT ID NCT03728972
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether the immune-boosting drug pembrolizumab can shrink early-stage NK/T-cell lymphoma in patients who have not yet had chemotherapy. Nineteen participants will receive the drug every three weeks. The goal is to see if this approach can control the disease without the need for standard chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (a drug that helps the immune system fight cancer)
- What this could lead to
- If successful, this could offer a chemotherapy-free option for early-stage NK/T-cell lymphoma, potentially reducing treatment side effects.
- What could go wrong
- This is a small pilot study with only 19 participants, so results may not apply to everyone. The drug may not shrink tumors effectively, and side effects like immune reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK/T-CELL LYMPHOMA OF NASAL CAVITY (DIAGNOSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack Meridian Health
Hackensack, New Jersey, 07601, United States
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
-
Stanford University
Stanford, California, 94305, United States